Farmacia Hospitalaria y Farmacogenómica

Chamorro-de-Vega, E; Gimenez-Manzorro, A; Rodriguez-Gonzalez, CG; Escudero-Vilaplana, V; Borrell, RC; Ibanez-Garcia, S; Sainz, EL; Matilla, EL; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Fernandez-Llamazares, CM; Marzal-Alfaro, M; Ribed, A; Jimenez, RMR; Gonzalez, CS; Herranz, A; Sanjurjo, M.

Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice

ANNALS OF PHARMACOTHERAPY. 2016; 50(11): 901-908 Nº de citas: 10 [doi:10.1177/1060028016659306]

de Lorenzo-Pinto, A; Llorente, BP.

Successful Treatment With Bosentan for Digital Ulcers Related to Mixed Cryoglobulinemia: A Case Report

AMERICAN JOURNAL OF THERAPEUTICS. 2016; 23(6): 1942-1943 Nº de citas: 2 [doi:10.1097/MJT.0000000000000384]

Manrique-Rodriguez, S; Sanchez-Galindo, AC; Fernandez-Llamazares, CM; Calvo-Calvo, MM; Carrillo-Alvarez, A; Sanjurjo-Saez, M.

Safe intravenous administration in pediatrics: A 5-year Pediatric Intensive Care Unit experience with smart pumps

Medicina Intensiva. 2016; 40(7): 411-421 Nº de citas: 11 [doi:10.1016/j.medin.2016.01.011]

Pascual-Pascual, SI; Nascimento, A; Fernandez-Llamazares, CM; Medrano-Lopez, C; Villalobos-Pinto, E; Martinez-Moreno, M; Ley, M; Manrique-Rodriguez, S; Blasco-Alonso, J.

Clinical guidelines for infantile-onset Pompe disease

REVISTA DE NEUROLOGIA. 2016; 63(6): 269-279 Nº de citas: 9 [doi:10.33588/rn.6306.2016232]

de Lorenzo-Pinto, A; Gimenez-Manzorro, A; Rodriguez-Gonzalez, CG; Ahumada-Jimenez, A; Herranz-Alonso, A; Marzal-Alfaro, MB; Sanjurjo-Saez, M.

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016; 41(4): 444-446 Nº de citas: 3 [doi:10.1111/jcpt.12403]

Gonzalez-Del Vecchio, M; Ruiz-Serrano, MJ; Gijon, P; Sanchez-Somolinos, M; de Egea, V; de Viedma, DG; Fresneda, MNS; Bouza, E.

Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2016; 85(3): 338-343 Nº de citas: 14 [doi:10.1016/j.diagmicrobio.2016.04.006]

Perez, RP; Garcia, BS; Llamazares, CMF; Artigao, FB; Julian, AN; Pena, MJM.

The challenge of administering anti-tuberculosis treatment in infants and pre-school children. pTBred Magistral Project

ANALES DE PEDIATRIA. 2016; 85(1): 4-12 Nº de citas: 11 [doi:10.1016/j.anpedi.2015.07.027]

Cortejoso, L; Garcia-Gonzalez, X; Garcia, MI; Garcia-Alfonso, P; Sanjurjo, M; Lopez-Fernandez, LA.

Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines

PHARMACOGENOMICS. 2016; 17(9): 979-984 Nº de citas: 40 [doi:10.2217/pgs-2016-0006]

Romero-Jimenez, RM; Escudero-Vilaplana, V; Baniandres Rodriguez, O; Garcia-Gonzalez, X; Sanjurjo Saez, M.

Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol

JOURNAL OF DERMATOLOGICAL TREATMENT. 2016; 27(3): 198-202 Nº de citas: 7 [doi:10.3109/09546634.2015.1088127]

De Lorenzo-Pinto, A; Garcia-Sanchez, R; Duran-Garcia, E; Castuera-Gil, A; Pascual-Izquierdo, C; Marzal-Alfaro, B; Arrabal-Duran, P; Herranz-Alonso, A; Andueza Lillo, JA; Sanjurjo-Saez, M.

Level of concordance between two risk-assessment models for predicting venous thromboembolism in medical patients at admission

EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2016; 23(3): 141-144 [doi:10.1136/ejhpharm-2015-000694]

Ribed, A; Escudero-Vilaplana, V; Romero-Jimenez, RM; Iglesias-Peinado, I; Herranz-Alonso, A; Sanjurjo-Saez, M.

Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents

EXPERT OPINION ON DRUG SAFETY. 2016; 15(4): 427-435 Nº de citas: 15 [doi:10.1517/14740338.2016.1150998]

Ibanez-Garcia, S; Rodriguez-Gonzalez, CG; Martin-Barbero, ML; Sanjurjo-Saez, M; Herranz-Alonso, A.

Adding value through pharmacy validation: a safety and cost perspective

JOURNAL OF EVALUATION IN CLINICAL PRACTICE. 2016; 22(2): 253-260 Nº de citas: 11 [doi:10.1111/jep.12466]

Ribed, A; Romero-Jimenez, RM; Escudero-Vilaplana, V; Iglesias-Peinado, I; Herranz-Alonso, A; Codina, C; Sanjurjo-Saez, M.

Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction

International Journal of Clinical Pharmacy. 2016; 38(2): 280-288 Nº de citas: 65 [doi:10.1007/s11096-015-0235-8]

Garcia-Gonzalez X; Cabaleiro T; Herrero MJ; McLeod H; Lopez-Fernandez LA.

Clinical implementation of pharmacogenetics.

Drug Metabolism And Personalized Therapy. 2016; 31(1): 9-16 [doi:10.1515/dmpt-2015-0031]

Escudero-Vilaplana, V; Garcia-Gonzalez, X; Osorio-Prendes, S; Romero-Jimenez, RM; Sanjurjo-Saez, M.

Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016; 41(1): 59-63 Nº de citas: 7 [doi:10.1111/jcpt.12348]

de Lorenzo-Pinto, A; Bueno, H; Cuellar-Basterrechea, B; Herranz-Alonso, A; Perez-Sanz, C; Rodriguez-Gonzalez, CG; Iglesias-Peinado, I; Fernandez-Aviles, F; Sanjurjo-Saez, M.

Optimisation of antithrombotic therapy in patients with acute coronary syndrome to reduce bleeding episodes

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2016; 70(2): 156-162 Nº de citas: 2 [doi:10.1111/ijcp.12766]

Collado-Borrell R; Escudero-Vilaplana V; Ribed-Sánchez A; Ibáñez-García S; Herranz-Alonso A; Sanjurjo-Sáez M.

Smartphone applications for cancer patients; what we know about them?

FARMACIA HOSPITALARIA. 2016; 40(1): 25-35 Nº de citas: 57 [doi:10.7399/fh.2016.40.1.8993]

Marzal-Alfaro, MB; Manrique-Rodriguez, S; Yeste-Gomez, I; Pernia-Lopez, MS; Sanjurjo-Saez, M; Fernandez-Llamazares, CM.

Palatability Assessment of Oral Liquid Compounding Products in a Tertiary Pediatric Hospital

LATIN AMERICAN JOURNAL OF PHARMACY. 2016; 35: 1234-1240